en · de · es · fr · pt
ghk-cu-notes.peptides1004.com › Faq › Chemical Identity Of Ghk-cu — Beginner to Advanced

Chemical Identity Of Ghk-cu — Beginner to Advanced

By Editorial Desk · published 2026-05-30 · last reviewed 2026-07-05 · Faq

The short version of Copper tripeptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.

Chemical Identity Of GHK-Cu

Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.

Biochemical Identity and Discovery

Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.

The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.

Ghk-cu at a glance

PropertyValueNotes
Chemical classCopper(II) peptide complexPeptide chain coordinated to a single metal ion
CAS number89030-95-5Indexed for the peptide-copper complex
Molecular formulaC14H22CuN6O4Approximate formula for a one-to-one complex
AppearanceBlue to violet solidColor from copper d-d transitions
Solubility classFreely soluble in waterAlso dispersible in some polar solvents

Identity And Molecular Background

The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.

Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.

Related pages on this site

Identity and Biochemical Background

The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.

GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.

Background and Chemical Identity

The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.

Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.

Supporting material

== Source == GsMTx-4 was isolated from the venom of Grammostola spatulata. After a blocking effect on mechanosensitive channels of the spider venom was detected in 1996, GsMTx-4 was isolated and identified from the venom later in 2000. Its concentration in the venom is ~2 mM.

In the English language, medical terms generally have a regular morphology, often being compound words that comprise three kinds of morphemes: roots, prefixes, and suffixes. The etymology of medical terms often originates from Latin (particularly Neo-Latin) and Ancient Greek, with such medical terms being examples of neoclassical compounds. Each language may supply relevant morphemes for medical terms. For example, there are two primary roots for medical terminology relating to kidneys – one from Greek (νεφρός nephr(os)) and one from Latin (ren(es)). Lexical items of medical terminology, which forms part of international scientific vocabulary (ISV), are translingual (that is, being used across multiple languages). The use of ISV was a driving force in the development of the constructed language known as Interlingua. From the 1950s to late 1970s, a number of medical journals were published, or used, Interlingua.

In an early media report on MDMA published in 1982, a Drug Enforcement Administration (DEA) spokesman stated the agency would ban the drug if enough evidence for abuse could be found. By mid-1984, MDMA use was becoming more noticed. Bill Mandel reported on "Adam" in a 10 June San Francisco Chronicle article, but misidentified the drug as methyloxymethylenedioxyamphetamine (MMDA). In the next month, the World Health Organization identified MDMA as the only substance out of twenty phenethylamines to be seized a significant number of times. After a year of planning and data collection, MDMA was proposed for scheduling by the DEA on 27 July 1984, with a request for comments and objections. The DEA was surprised when a number of psychiatrists, psychotherapists, and researchers objected to the proposed scheduling and requested a hearing. In a Newsweek article published the next year, a DEA pharmacologist stated that the agency had been unaware of its use among psychiatrists. An initial hearing was held on 1 February 1985 at the DEA offices in Washington, D.C., with administrative law judge Francis L. Young presiding. It was decided there to hold three more hearings that year: Los Angeles on 10 June, Kansas City, Missouri on 10–11 July, and Washington, D.C., on 8–11 October. Sensational media attention was given to the proposed criminalization and the reaction of MDMA proponents, effectively advertising the drug.

Bronopol (INN; chemical name 2-bromo-2-nitropropane-1,3-diol) is an organic compound that is used as an antimicrobial. It is a white solid although commercial samples appear yellow. The first reported synthesis of bronopol was in 1897. Bronopol was invented by The Boots Company PLC in the early 1960s and first applications were as a preservative for pharmaceuticals. Due to its low mammalian toxicity at in-use levels and high activity against bacteria, especially Gram-negative species, bronopol became popular as a preservative in many consumer products such as shampoos and cosmetics. It was subsequently adopted as an antimicrobial in other industrial environments such as paper mills, oil exploration, and production facilities, as well as cooling water disinfection plants.

== US Food and Drug Administration == (21 CFR Part 58) The FDA requires nonclinical laboratory studies on new drugs, food additives, and chemicals to assess their safety and potential effectiveness in humans in compliance with 21 CFR Part 58, Good Laboratory Practice for Nonclinical Studies under the Federal Food Drug and Cosmetic Act and Public Health Service Act. These regulations set the standards for conducting experimental laboratory studies that support or are intended to support applications for research or marketing permits for products such as food additives, drugs, medical devices, or biological products. Conducting these studies with rigorous adherence to scientific principles and quality control is crucial, as the decisions based on their outcomes directly affect human health and safety. By adhering to the requirements outlined in 21 CFR Part 58, laboratories conducting laboratory studies can ensure that the data generated are of high quality, reliable, and suitable for submission to the Agency as part of product approval processes. Compliance with GLP regulations helps to protect the safety and welfare of humans and animals involved in studies and contributes to the overall integrity of scientific research in the development of FDA-regulated products. GLP compliance inspections are assessed and performed under the Agency's Bioresearch Monitoring (BIMO) program and carried out by trained BIMO inspectors. Serious noncompliance is dealt with by procedures ranging from study rejection to laboratory disqualification.

Sources: en.wikipedia.org

Supporting material

=== Pharmacokinetics === Etifoxine is taken via oral administration. It is rapidly absorbed from the gastrointestinal tract. It is well-absorbed, with a bioavailability of 90%. The time to peak levels of etifoxine is 2 to 3 hours. The plasma protein binding of etifoxine is 88 to 95%. It does not bind to blood cells. The drug is known to cross the placental barrier. Etifoxine is metabolized in the liver into several metabolites. One of these metabolites, diethyletifoxine, is pharmacologically active. The elimination half-life of etifoxine is 6 hours and of diethyletifoxine is almost 20 hours. Etifoxine is eliminated in three phases. The drug is excreted mainly in urine in the form of metabolites. It is also excreted in bile. Only small amounts are excreted unchanged.

Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids.

==== Therapy-related ==== Medical treatment can directly or indirectly cause weight loss, impairing treatment effectiveness and recovery that can lead to further weight loss in a vicious cycle. Many patients will be in pain and have a loss of appetite after surgery. Part of the body's response to surgery is to direct energy to wound healing, which increases the body's overall energy requirements. Surgery affects nutritional status indirectly, particularly during the recovery period, as it can interfere with wound healing and other aspects of recovery. Surgery directly affects nutritional status if a procedure permanently alters the digestive system. Enteral nutrition (tube feeding) is often needed. However a policy of 'nil by mouth' for all gastrointestinal surgery has not been shown to benefit, with some weak evidence suggesting it might hinder recovery. Early post-operative nutrition is a part of Enhanced Recovery After Surgery protocols. These protocols also include carbohydrate loading in the 24 hours before surgery, but earlier nutritional interventions have not been shown to have a significant impact.

NAA60 is a protein belonging to the family of N-terminal acetyltransferases (NATs), which catalyze the transfer of an acetyl group from acetyl-coenzyme A (Ac-CoA) to the N-terminus of proteins. NAA60 is specifically localized to the Golgi apparatus and can acetylate membrane proteins post-translationally that have cytosolic N-termini starting with methionine followed by hydrophobic- or amphipathic-type amino acids (ML-, MI-, MF-, MY-, and MK-).

Sources: en.wikipedia.org

Supporting material

=== Reducing toxic effects of alcohol === Cysteine has been proposed as a preventive or antidote for some of the negative effects of alcohol, including liver damage and hangover. It counteracts the poisonous effects of acetaldehyde. It binds to acetaldehyde to form the low-toxicity heterocycle methylthioproline. In a rat study, test animals received an LD90 dose of acetaldehyde. Those that received cysteine had an 80% survival rate; when both cysteine and thiamine were administered, all animals survived. The control group had a 10% survival rate. In 2020 an article was published that suggests L-cysteine might also work in humans.

Historians credited the increased marketing of skin whiteners to the culture of the Jim Crow era, as black Americans faced continued social and legal restrictions. Cosmetic advertisements directed at black consumers often framed resulting lighter complexions as cleaner and better. Simultaneously, cosmetic and beauty magazines often published criticisms of black women who used skin bleachers, arguing that they appeared unnatural and fraudulent. In the 1930s, tanned skin became popular among white women as a new symbol of wealth. Some historians assert that industrialization had created indoor settings for labor, causing tanned skin to be associated more with sunbathing, travel, and leisure. The growth of the Black is Beautiful movement in the 1960s, combined with greater awareness of potential health hazards, also temporarily slowed the sale and popularity of skin bleachers. However, by the 1980s, paler skin once again became more desirable, as tanning became linked to premature aging and sun damage.

=== 19th century === Since the late nineteenth century, breast implants have been used to surgically augment the size (volume), modify the shape (contour), and enhance the feel (tact) of a woman's breasts. In 1895, surgeon Vincenz Czerny effected the earliest breast implant emplacement when he used the patient's autologous adipose tissue, harvested from a benign lumbar lipoma, to repair the asymmetry of the breast from which he had removed a tumor. In 1889, surgeon Robert Gersuny experimented with paraffin injections, with disastrous results arising from the breakup of the paraffin into smaller bodies following the procedure.

== Preparation == Divinyl sulfone is prepared from the diacetate bis(2-hydroxyethyl)sulfide. Oxidation of this diester with hydrogen peroxide gives the sulfone. The sulfone is then pyrolyzed to induce elimination of two equivalents of acetic acid:

Amadori rearrangement Carbohydrate acetalisation Carbohydrate digestion Cyanohydrin reaction Koenigs–Knorr reaction Lobry de Bruyn–Van Ekenstein transformation Nef reaction Wohl degradation Tipson-Cohen reaction Ferrier rearrangement Ferrier II reaction Related topics

Sources: en.wikipedia.org

Frequently asked questions

What is GHK-Cu?

It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.

Where does the GHK sequence come from?

The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.

Is GHK-Cu an approved drug?

It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.

What is the difference between GHK and GHK-Cu?

GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.

Network